Karyopharm Announces a Phase 1 Trial of Selinexor (KPT-330) in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
April 21, 2014 at 07:06 AM EDT
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel ...
